As stated in the past Oncosec sees an exit opportunity with PISCES data release. If the news is good I do believe they get a buyout offer from Merck. At this point does Oncosec accept an offer. With the possibility to expand the pipeline and grow organically...TNBC news from AACR will shed more light on things. Maybe they decide to stick with licensing or maybe a buyout offer will be much higher than expected and too good to pass up.